BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tagraxofusp readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tagraxofusp\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06414681-2839@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tagraxofusp: Phase 1 readout est. (NCT06414681)
DESCRIPTION:Tagraxofusp\, phase 1.\nStudy: Combination of Tagraxofusp With 
 Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis\, Who H
 ave Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy
  With the Approved JAK Inhibitors is Not Appropriate\, Contraindicated or 
 Declined\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tagraxofusp#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06414681
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04216524-2839@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tagraxofusp: Phase 2 readout est. (NCT04216524)
DESCRIPTION:Tagraxofusp\, phase 2.\nStudy: Venetoclax\, SL-401\, and Chemot
 herapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm\n
 Estimated primary completion: 31 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tagraxofusp#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04216524
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05038592-2839@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Tagraxofusp: Phase 1/2 readout est. (NCT05038592)
DESCRIPTION:Tagraxofusp\, phase 1/2.\nStudy: Phase I/II Study of Tagraxofus
 p in Combination With Decitabine for Patients With Myelomonocytic/Myelopro
 liferative Neoplasm and High Risk Myelodysplastic Syndromes\nEstimated pri
 mary completion: 29 January 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tagraxofusp#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05038592
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06498973-2839@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:Tagraxofusp: Phase 1 readout est. (NCT06498973)
DESCRIPTION:Tagraxofusp\, phase 1\, Acute Myeloid Leukemia.\nStudy: Tagraxo
 fusp and Azacitidine for Maintenance Treatment in Patients With CD123 Posi
 tive AML and MDS Following Donor Hematopoietic Cell Transplant\nEstimated 
 primary completion: 25 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tagraxofusp#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06498973
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561152-2839@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tagraxofusp: Phase 1/2 readout est. (NCT06561152)
DESCRIPTION:Tagraxofusp\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Tagra
 xofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refra
 ctory AML\nEstimated primary completion: October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tagraxofusp#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06561152
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456463-2839@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Tagraxofusp: Phase 2 readout est. (NCT06456463)
DESCRIPTION:Tagraxofusp\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults W
 ith Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive C
 hemotherapy\nEstimated primary completion: 9 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tagraxofusp#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06456463
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007052-2839@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20281210
DTEND;VALUE=DATE:20281211
SUMMARY:Tagraxofusp: Phase 2 readout est. (NCT07007052)
DESCRIPTION:Tagraxofusp\, phase 2.\nStudy: Phase II Study Evaluating the Ef
 ficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Trea
 tment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients\nEstimat
 ed primary completion: 10 December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tagraxofusp#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07007052
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07148180-2839@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tagraxofusp: Phase 1/2 readout est. (NCT07148180)
DESCRIPTION:Tagraxofusp\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Mul
 ti-Site Break Through Cancer Trial: Targeting Measurable Residual Disease 
 in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp\
 , Azacitidine\, and Venetoclax\nEstimated primary completion: 31 December 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tagraxofusp#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0714818
 0
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949370-2839@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tagraxofusp: Phase 2 readout est. (NCT07949370)
DESCRIPTION:Tagraxofusp\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase
  2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subj
 ects With R/R AML\nEstimated primary completion: 31 December 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tagraxofusp#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07949370
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05442216-2839@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20300721
DTEND;VALUE=DATE:20300722
SUMMARY:Tagraxofusp: Phase 2 readout est. (NCT05442216)
DESCRIPTION:Tagraxofusp\, phase 2\, Acute Myeloid Leukemia.\nStudy: Tagraxo
 fusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML Afte
 r Hypomethylating Agents\nEstimated primary completion: 21 July 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tagraxofusp#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05442216
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
